Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV
Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
Cytomegalovirus (CMV) infection is a common opportunistic infection (OI) in HIV patients. The
purpose of this study is to find out whether valganciclovir, an antiviral approved by the FDA
for the treatment of CMV in the eye, is safe and effective in preventing CMV organ damage in
people with HIV.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)